|
SK285141B6
(sk)
|
1996-02-13 |
2006-07-07 |
Astrazeneca Uk Limited |
Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje
|
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
|
ATE211134T1
(de)
|
1996-03-05 |
2002-01-15 |
|
4-anilinochinazolin derivate
|
|
GB9707800D0
(en)
|
1996-05-06 |
1997-06-04 |
Zeneca Ltd |
Chemical compounds
|
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
|
CA2263479A1
(en)
|
1996-09-25 |
1998-04-02 |
Zeneca Limited |
Quinoline derivatives inhibiting the effect of growth factors such as vegf
|
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
|
ATE368665T1
(de)
|
1997-08-22 |
2007-08-15 |
Astrazeneca Ab |
Oxindolylchinazolinderivate als angiogenesehemmer
|
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
|
US6297258B1
(en)
|
1998-09-29 |
2001-10-02 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
|
US6288082B1
(en)
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
|
BRPI9914164B8
(pt)
|
1998-09-29 |
2021-05-25 |
American Cyanamid Co |
compostos de 3-ciano quinolina
|
|
ES2241324T3
(es)
|
1998-10-08 |
2005-10-16 |
Astrazeneca Ab |
Derivados de quinazolina.
|
|
UA71945C2
(en)
*
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
|
SK288138B6
(sk)
|
1999-02-10 |
2013-11-04 |
Astrazeneca Ab |
Quinazoline derivatives as angiogenesis inhibitors
|
|
GB9904103D0
(en)
*
|
1999-02-24 |
1999-04-14 |
Zeneca Ltd |
Quinoline derivatives
|
|
GB9910580D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
|
GB9910579D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
|
ATE253915T1
(de)
|
1999-06-30 |
2003-11-15 |
Merck & Co Inc |
Src-kinase hemmende verbindungen
|
|
EP1194152A4
(en)
|
1999-06-30 |
2002-11-06 |
Merck & Co Inc |
Links to SRC kinase inhibition
|
|
WO2001000207A1
(en)
|
1999-06-30 |
2001-01-04 |
Merck & Co., Inc. |
Src kinase inhibitor compounds
|
|
DE60037020T2
(de)
|
1999-07-09 |
2008-08-21 |
Glaxo Group Ltd., Greenford |
Anilinochinazoline als protein-tyrosin-kinasehemmer
|
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
|
WO2002049993A2
(en)
*
|
2000-09-29 |
2002-06-27 |
Neurogen Corporation |
High affinity small molecule c5a receptor modulators
|
|
HU229414B1
(hu)
|
1999-11-05 |
2013-12-30 |
Astrazeneca Ab |
Kinazolin-származékok mint VEGF-inhibitorok, eljárás az elõállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
|
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
|
UA75055C2
(uk)
*
|
1999-11-30 |
2006-03-15 |
Пфайзер Продактс Інк. |
Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
|
|
US6638929B2
(en)
|
1999-12-29 |
2003-10-28 |
Wyeth |
Tricyclic protein kinase inhibitors
|
|
GB0002952D0
(en)
*
|
2000-02-09 |
2000-03-29 |
Pharma Mar Sa |
Process for producing kahalalide F compounds
|
|
CN1240688C
(zh)
|
2000-04-07 |
2006-02-08 |
阿斯特拉曾尼卡有限公司 |
喹唑啉化合物
|
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
|
ATE353891T1
(de)
*
|
2000-06-30 |
2007-03-15 |
Glaxo Group Ltd |
Ditosylatsalze von chinazolinverbindungen
|
|
BR0113056A
(pt)
|
2000-08-09 |
2003-07-08 |
Astrazeneca Ab |
Composto, processo papa a preparação do mesmo, composição farmacêutica, e, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente, e, uso de um composto
|
|
US7115615B2
(en)
|
2000-08-21 |
2006-10-03 |
Astrazeneca |
Quinazoline derivatives
|
|
DE60128709T2
(de)
|
2000-09-15 |
2007-12-27 |
Vertex Pharmaceuticals Inc., Cambridge |
Triazol-verbindungen als protein-kinase-inhibitoren
|
|
US7473691B2
(en)
|
2000-09-15 |
2009-01-06 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
US6660731B2
(en)
|
2000-09-15 |
2003-12-09 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
CN1474816A
(zh)
*
|
2000-09-20 |
2004-02-11 |
Ĭ��ר���ɷ�����˾ |
4-氨基-喹唑啉
|
|
US7547702B2
(en)
*
|
2000-09-20 |
2009-06-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
4-amino-quinazolines
|
|
AU2001292138A1
(en)
|
2000-10-13 |
2002-04-22 |
Astrazeneca Ab |
Quinazoline derivatives with anti-tumour activity
|
|
EP1326860A1
(en)
|
2000-10-13 |
2003-07-16 |
AstraZeneca AB |
Quinazoline derivatives
|
|
DE60126997T2
(de)
|
2000-10-20 |
2007-10-25 |
Eisai R&D Management Co., Ltd. |
Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
|
|
WO2002044166A1
(en)
|
2000-11-02 |
2002-06-06 |
Astrazeneca Ab |
Substituted quinolines as antitumor agents
|
|
EP1337513A1
(en)
|
2000-11-02 |
2003-08-27 |
AstraZeneca AB |
4-substituted quinolines as antitumor agents
|
|
NZ526468A
(en)
|
2000-12-21 |
2004-03-26 |
Vertex Pharma |
Pyrazole compounds useful as protein kinase inhibitors
|
|
EP2796468A2
(en)
|
2001-01-05 |
2014-10-29 |
Pfizer Inc |
Antibodies to insulin-like growth factor I receptor
|
|
EP1353693B1
(en)
|
2001-01-16 |
2005-03-16 |
Glaxo Group Limited |
Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
|
|
EP1370553B1
(en)
*
|
2001-03-23 |
2006-05-10 |
Bayer Corporation |
Rho-kinase inhibitors
|
|
MXPA03008659A
(es)
*
|
2001-03-23 |
2005-04-08 |
Bayer Ag |
Inhibidores de rho-cinasa.
|
|
DE60229046D1
(de)
|
2001-04-19 |
2008-11-06 |
Astrazeneca Ab |
Chinazolin derivate
|
|
GB0112836D0
(en)
|
2001-05-25 |
2001-07-18 |
Smithkline Beecham Plc |
Medicaments
|
|
GB0112834D0
(en)
|
2001-05-25 |
2001-07-18 |
Smithkline Beecham Plc |
Medicaments
|
|
WO2003000194A2
(en)
|
2001-06-21 |
2003-01-03 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
|
US7829566B2
(en)
*
|
2001-09-17 |
2010-11-09 |
Werner Mederski |
4-amino-quinazolines
|
|
GB0126433D0
(en)
*
|
2001-11-03 |
2002-01-02 |
Astrazeneca Ab |
Compounds
|
|
ES2320980T3
(es)
*
|
2001-11-03 |
2009-06-01 |
Astrazeneca Ab |
Derivados de quinazolina como agentes antitumorales.
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
MXPA04005678A
(es)
*
|
2001-12-12 |
2004-12-06 |
Pfizer Prod Inc |
Formas de sal de e-2 -metoxi -n- (3- (4- (3-metil -piridin-3- iloxil ) fenilamino) quinazolin -6-il) alil) alil) acetamida, su preparacion y su uso contra el cancer.
|
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
|
JP4505228B2
(ja)
*
|
2002-01-10 |
2010-07-21 |
バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト |
Ｒｈｏ−キナーゼ阻害剤
|
|
JP2005526714A
(ja)
*
|
2002-01-17 |
2005-09-08 |
ニューロジェン・コーポレーション |
カプサイシンのモジュレーターとしての置換キナゾリン−４−イルアミン類縁体
|
|
ES2298497T3
(es)
|
2002-01-23 |
2008-05-16 |
Bayer Pharmaceuticals Corporation |
Inhibidores de quinasa rho.
|
|
CA2473510A1
(en)
|
2002-01-23 |
2003-07-31 |
Bayer Pharmaceuticals Corporation |
Pyrimidine derivatives as rho-kinase inhibitors
|
|
UA81619C2
(ru)
|
2002-02-01 |
2008-01-25 |
Астразенека Аб |
Хиназолиновые соединения, способ их получения (варианты), фармацевтическая композиция на их основе
|
|
US7645878B2
(en)
*
|
2002-03-22 |
2010-01-12 |
Bayer Healthcare Llc |
Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
|
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
|
JP2005534623A
(ja)
*
|
2002-04-08 |
2005-11-17 |
スミスクライン ビーチャム コーポレーション |
Ｅｒｂファミリーの阻害剤並びにｒａｆ及び／又はｒａｓ阻害剤を投与することを含む癌の治療法
|
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
|
MY141867A
(en)
|
2002-06-20 |
2010-07-16 |
Vertex Pharma |
Substituted pyrimidines useful as protein kinase inhibitors
|
|
WO2004004732A1
(en)
|
2002-07-09 |
2004-01-15 |
Astrazeneca Ab |
Quinazoline derivatives for use in the treatment of cancer
|
|
GB0215823D0
(en)
|
2002-07-09 |
2002-08-14 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
EP2277867B1
(en)
|
2002-07-15 |
2012-12-05 |
Symphony Evolution, Inc. |
Compounds, pharmaceutical compositions thereof and their use in treating cancer
|
|
AU2003250701A1
(en)
*
|
2002-07-31 |
2004-02-16 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
|
ZA200501124B
(en)
|
2002-08-02 |
2006-10-25 |
Vertex Pharma |
Pyrazole compositions useful as inhibitors of GSK-3
|
|
US7629347B2
(en)
*
|
2002-10-09 |
2009-12-08 |
Critical Outcome Technologies, Inc. |
Protein tyrosine kinase inhibitors
|
|
GB0304367D0
(en)
*
|
2003-02-26 |
2003-04-02 |
Pharma Mar Sau |
Methods for treating psoriasis
|
|
GB0225579D0
(en)
|
2002-11-02 |
2002-12-11 |
Astrazeneca Ab |
Chemical compounds
|
|
PL215161B1
(pl)
|
2002-11-04 |
2013-10-31 |
Astrazeneca Ab |
Pochodne chinazoliny, sposób ich wytwarzania, kompozycje farmaceutyczne je zawierajace oraz ich zastosowanie
|
|
US7488823B2
(en)
*
|
2003-11-10 |
2009-02-10 |
Array Biopharma, Inc. |
Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
|
|
AU2003300898A1
(en)
*
|
2002-12-13 |
2004-07-09 |
Neurogen Corporation |
Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
|
|
SI1585743T1
(sl)
|
2002-12-19 |
2007-08-31 |
Pfizer |
Spojine 2-(1H-indazol-6-ilamino)-benzamida kot inhibitorji protein-kinaz, uporabnih pri zdravljenju očesnih bolezni
|
|
DK1625121T3
(da)
|
2002-12-20 |
2010-05-10 |
Pfizer Prod Inc |
Pyrimidinderivater til behandling af abnorm cellevækst
|
|
ES2502490T3
(es)
|
2003-02-26 |
2014-10-03 |
Sugen, Inc. |
Compuestos aminoheteroarílicos como inhibidores de proteín quinasas
|
|
CA2517291C
(en)
*
|
2003-03-19 |
2012-05-08 |
Exelixis, Inc. |
Ortho-substituted aryl and heteroaryl tie-2 modulators and methods of use
|
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
TWI328009B
(en)
|
2003-05-21 |
2010-08-01 |
Glaxo Group Ltd |
Quinoline derivatives as phosphodiesterase inhibitors
|
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
|
US7618975B2
(en)
*
|
2003-07-03 |
2009-11-17 |
Myriad Pharmaceuticals, Inc. |
4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
|
|
AR045037A1
(es)
|
2003-07-10 |
2005-10-12 |
Aventis Pharma Sa |
Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
|
|
TW200510373A
(en)
*
|
2003-07-14 |
2005-03-16 |
Neurogen Corp |
Substituted quinolin-4-ylamine analogues
|
|
US7329664B2
(en)
*
|
2003-07-16 |
2008-02-12 |
Neurogen Corporation |
Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
|
|
WO2005011607A2
(en)
*
|
2003-08-01 |
2005-02-10 |
Smithkline Beecham Corporation |
Treatment of cancers expressing p95 erbb2
|
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
|
CN103772373B
(zh)
|
2003-08-14 |
2017-06-09 |
阿雷生物药品公司 |
作为受体酪氨酸激酶抑制剂的喹唑啉类似物
|
|
US7501427B2
(en)
|
2003-08-14 |
2009-03-10 |
Array Biopharma, Inc. |
Quinazoline analogs as receptor tyrosine kinase inhibitors
|
|
MXPA06002296A
(es)
|
2003-08-29 |
2006-05-22 |
Pfizer |
Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos.
|
|
CA2537883A1
(en)
*
|
2003-09-09 |
2005-03-17 |
Neurogen Corporation |
Substituted bicyclic quinazolin-4-ylamine derivatives
|
|
GB0321066D0
(en)
*
|
2003-09-09 |
2003-10-08 |
Pharma Mar Sau |
New antitumoral compounds
|
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
SI1667991T1
(sl)
|
2003-09-16 |
2008-10-31 |
Astrazeneca Ab |
Kinazolinski derivati kot inhibitorji tirozin kinaze
|
|
GB0322409D0
(en)
|
2003-09-25 |
2003-10-29 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
PL2392565T3
(pl)
|
2003-09-26 |
2014-08-29 |
Exelixis Inc |
Modulatory c-Met i sposoby stosowania
|
|
US7683172B2
(en)
|
2003-11-11 |
2010-03-23 |
Eisai R&D Management Co., Ltd. |
Urea derivative and process for preparing the same
|
|
US7511065B2
(en)
*
|
2003-11-12 |
2009-03-31 |
Eli Lilly And Company |
Mixed lineage kinase modulators
|
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
ATE473967T1
(de)
*
|
2003-11-26 |
2010-07-15 |
Pfizer Prod Inc |
Aminopyrazolderivate als gsk-3-inhibitoren
|
|
GB0330002D0
(en)
|
2003-12-24 |
2004-01-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US7632840B2
(en)
|
2004-02-03 |
2009-12-15 |
Astrazeneca Ab |
Quinazoline compounds for the treatment of hyperproliferative disorders
|
|
KR20080095915A
(ko)
|
2004-05-06 |
2008-10-29 |
워너-램버트 캄파니 엘엘씨 |
4-페닐아미노-퀴나졸린-6-일-아미드
|
|
WO2005120509A1
(en)
|
2004-06-04 |
2005-12-22 |
Amphora Discovery Corporation |
Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
|
|
EP2322215A3
(en)
|
2004-07-16 |
2011-09-28 |
Pfizer Products Inc. |
Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
|
|
NZ552866A
(en)
|
2004-08-26 |
2010-06-25 |
Pfizer |
Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
|
|
CN101056639A
(zh)
|
2004-09-15 |
2007-10-17 |
詹森药业有限公司 |
噻唑并吡啶激酶抑制剂
|
|
US8969379B2
(en)
|
2004-09-17 |
2015-03-03 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
|
|
US20070054916A1
(en)
*
|
2004-10-01 |
2007-03-08 |
Amgen Inc. |
Aryl nitrogen-containing bicyclic compounds and methods of use
|
|
TW200621251A
(en)
|
2004-10-12 |
2006-07-01 |
Neurogen Corp |
Substituted biaryl quinolin-4-ylamine analogues
|
|
ATE501148T1
(de)
|
2004-12-14 |
2011-03-15 |
Astrazeneca Ab |
Pyrazolopyrimidinverbindungen als antitumormittel
|
|
US8258145B2
(en)
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
|
CA2592900A1
(en)
|
2005-01-03 |
2006-07-13 |
Myriad Genetics Inc. |
Nitrogen containing bicyclic compounds and therapeutical use thereof
|
|
US20060188498A1
(en)
*
|
2005-02-18 |
2006-08-24 |
Genentech, Inc. |
Methods of using death receptor agonists and EGFR inhibitors
|
|
US20090155247A1
(en)
*
|
2005-02-18 |
2009-06-18 |
Ashkenazi Avi J |
Methods of Using Death Receptor Agonists and EGFR Inhibitors
|
|
RU2414457C2
(ru)
*
|
2005-02-23 |
2011-03-20 |
Сионоги Энд Ко., Лтд. |
Производные хиназолина, обладающие ингибирующей активностью в отношении тирозинкиназы
|
|
RU2413735C2
(ru)
|
2005-03-31 |
2011-03-10 |
Эдженсис, Инк. |
Антитела и родственные молекулы, связывающиеся с белками 161p2f10b
|
|
KR100990027B1
(ko)
|
2005-04-26 |
2010-10-26 |
화이자 인코포레이티드 |
Ｐ-카드헤린 항체
|
|
GB0508715D0
(en)
*
|
2005-04-29 |
2005-06-08 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2006118749A1
(en)
|
2005-05-04 |
2006-11-09 |
Janssen Pharmaceutica, N.V. |
Thia-tetraazaacenaphthylene kinase inhibitors
|
|
BRPI0614483A2
(pt)
|
2005-07-27 |
2011-03-29 |
Hoffmann La Roche |
ariloxiquinolinas e usos das mesmas como 5-ht6
|
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
|
PT1933871E
(pt)
|
2005-09-07 |
2013-07-17 |
Pfizer |
Anticorpos monoclonais humanos para cinase-1 do tipo receptor de activina
|
|
US7732613B2
(en)
*
|
2005-09-14 |
2010-06-08 |
Bristol-Myers Squibb Company |
Met kinase inhibitors
|
|
ATE533057T1
(de)
|
2005-09-20 |
2011-11-15 |
Osi Pharm Inc |
Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
|
|
US7820683B2
(en)
|
2005-09-20 |
2010-10-26 |
Astrazeneca Ab |
4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
|
|
GB0520475D0
(en)
*
|
2005-10-07 |
2005-11-16 |
Arrow Therapeutics Ltd |
Chemical compounds
|
|
RU2008122070A
(ru)
|
2005-11-03 |
2009-12-10 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Аминопиридины, используемые в качестве ингибиторов киназ
|
|
ES2364901T3
(es)
|
2005-11-15 |
2011-09-16 |
Array Biopharma, Inc. |
Procesos e intermedios para la preparación de derivados de n4-fenil-quinazolin-4-amina.
|
|
CA2635916A1
(en)
*
|
2006-01-11 |
2007-07-19 |
Arrow Therapeutics Limited |
Triazoloanilinopyrimidine derivatives for use as antiviral agents
|
|
DE102006012251A1
(de)
*
|
2006-03-15 |
2007-11-08 |
Grünenthal GmbH |
Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
|
|
UA91129C2
(ru)
|
2006-05-09 |
2010-06-25 |
Пфайзер Продактс Инк. |
Производные циклоалкиламинокислот и фармацевтическая композиция, которая их содержит
|
|
NL2000613C2
(nl)
|
2006-05-11 |
2007-11-20 |
Pfizer Prod Inc |
Triazoolpyrazinederivaten.
|
|
JP5190361B2
(ja)
|
2006-05-18 |
2013-04-24 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
甲状腺癌に対する抗腫瘍剤
|
|
WO2008016123A1
(en)
*
|
2006-08-03 |
2008-02-07 |
Takeda Pharmaceutical Company Limited |
GSK-3β INHIBITOR
|
|
US20110053964A1
(en)
*
|
2006-08-22 |
2011-03-03 |
Roger Tung |
4-aminoquinazoline derivatives and methods of use thereof
|
|
KR20090042994A
(ko)
*
|
2006-08-22 |
2009-05-04 |
콘서트 파마슈티컬즈, 인크. |
4-아미노퀴나졸린 유도체 및 이의 사용방법
|
|
CN101511793B
(zh)
|
2006-08-28 |
2011-08-03 |
卫材R&D管理有限公司 |
针对未分化型胃癌的抗肿瘤剂
|
|
ES2372217T3
(es)
|
2006-09-12 |
2012-01-17 |
Genentech, Inc. |
Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de pdgfra, kit o kdr como marcador genético.
|
|
KR101129868B1
(ko)
*
|
2006-10-04 |
2012-04-12 |
화이자 프로덕츠 인코포레이티드 |
칼슘 수용체 길항제로서의 피리도［4,3-ｄ］피리미딘-4(3Ｈ)-온 유도체
|
|
WO2008058126A2
(en)
|
2006-11-06 |
2008-05-15 |
Supergen, Inc. |
Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
|
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
|
US8034815B2
(en)
|
2007-01-11 |
2011-10-11 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
|
WO2008093855A1
(ja)
|
2007-01-29 |
2008-08-07 |
Eisai R & D Management Co., Ltd. |
未分化型胃癌治療用組成物
|
|
JP5377332B2
(ja)
|
2007-02-06 |
2013-12-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
|
|
US7776857B2
(en)
|
2007-04-05 |
2010-08-17 |
Amgen Inc. |
Aurora kinase modulators and method of use
|
|
JP5926487B2
(ja)
|
2007-04-13 |
2016-05-25 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
ＥｒｂＢ療法に耐性である癌を治療するための方法
|
|
ES2593486T3
(es)
|
2007-04-18 |
2016-12-09 |
Pfizer Products Inc. |
Derivados de sulfonil amida para el tratamiento del crecimiento celular anómalo
|
|
NZ580884A
(en)
|
2007-05-02 |
2012-02-24 |
Vertex Pharma |
Thiazoles and pyrazoles useful as kinase inhibitors
|
|
CN101367794B
(zh)
*
|
2007-07-20 |
2013-07-10 |
上海恒瑞医药有限公司 |
喹唑啉类衍生物的制备方法及其在医药上的应用
|
|
WO2009012647A1
(fr)
*
|
2007-07-20 |
2009-01-29 |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Procédés de préparation de dérivés de quinazoline et leurs utilisations pharmaceutiques
|
|
AR067762A1
(es)
|
2007-07-31 |
2009-10-21 |
Vertex Pharma |
Proceso para preparar 5-fluoro-1h-pirazolo (3,4-b) piridin-3-amina y derivados de la misma
|
|
PT2188313T
(pt)
|
2007-08-21 |
2017-12-12 |
Amgen Inc |
Proteínas de ligação ao antigénio c-fms humano
|
|
EP2185574B1
(en)
|
2007-09-07 |
2013-05-08 |
Agensys, Inc. |
Antibodies and related molecules that bind to 24p4c12 proteins
|
|
JP2011500723A
(ja)
*
|
2007-10-19 |
2011-01-06 |
ファルマ・マール・ソシエダード・アノニマ |
改善された抗腫瘍治療
|
|
US8080558B2
(en)
|
2007-10-29 |
2011-12-20 |
Natco Pharma Limited |
4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent
|
|
EP2218712B1
(en)
|
2007-11-09 |
2015-07-01 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
|
US20110053991A1
(en)
*
|
2007-11-19 |
2011-03-03 |
Gore Lia |
Treatment of Histone Deacetylase Mediated Disorders
|
|
WO2009079797A1
(en)
|
2007-12-26 |
2009-07-02 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
WO2009095480A1
(en)
*
|
2008-01-30 |
2009-08-06 |
Pharma Mar, S.A. |
Improved antitumoral treatments
|
|
BRPI0907916A2
(pt)
|
2008-02-07 |
2015-07-28 |
Boehringer Ingelheim Int |
Heterociclos espirociclos, medicamentos contendo esses compostos, e processos para preparar os mesmos
|
|
CN101965192A
(zh)
*
|
2008-03-07 |
2011-02-02 |
法马马有限公司 |
改善的抗肿瘤治疗
|
|
EP2288611B1
(en)
|
2008-03-20 |
2013-05-15 |
Amgen Inc. |
Aurora kinase modulators and method of use
|
|
WO2009126662A1
(en)
*
|
2008-04-08 |
2009-10-15 |
Syndax Pharmaceuticals, Inc. |
Administration of an inhibitor of hdac, an inhibitor of her-2, and a selective estrogen receptor modulator
|
|
WO2009137714A2
(en)
*
|
2008-05-07 |
2009-11-12 |
Teva Pharmaceutical Industries Ltd. |
Forms of lapatinib ditosylate and processes for preparation thereof
|
|
AU2009247782C1
(en)
|
2008-05-13 |
2013-09-19 |
Astrazeneca Ab |
Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline
|
|
CN101584696A
(zh)
|
2008-05-21 |
2009-11-25 |
上海艾力斯医药科技有限公司 |
包含喹唑啉衍生物的组合物及制备方法、用途
|
|
CA2999321A1
(en)
|
2008-07-17 |
2010-01-21 |
Critical Outcome Technologies Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
|
WO2010017387A2
(en)
*
|
2008-08-06 |
2010-02-11 |
Teva Pharmaceutical Industries Ltd. |
Lapatinib intermediates
|
|
US8648191B2
(en)
|
2008-08-08 |
2014-02-11 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
|
US9126935B2
(en)
|
2008-08-14 |
2015-09-08 |
Amgen Inc. |
Aurora kinase modulators and methods of use
|
|
US20100087459A1
(en)
*
|
2008-08-26 |
2010-04-08 |
Leonid Metsger |
Forms of lapatinib compounds and processes for the preparation thereof
|
|
KR20110058866A
(ko)
*
|
2008-09-02 |
2011-06-01 |
노파르티스 아게 |
비시클릭 키나제 억제제
|
|
AU2009288200A1
(en)
|
2008-09-03 |
2010-03-11 |
Vertex Pharmaceuticals Incorporated |
Co-crystals and pharmaceutical formulations comprising the same
|
|
TW201014860A
(en)
|
2008-09-08 |
2010-04-16 |
Boehringer Ingelheim Int |
New chemical compounds
|
|
US8476410B2
(en)
|
2008-10-16 |
2013-07-02 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
|
|
EP2349235A1
(en)
|
2008-11-07 |
2011-08-03 |
Triact Therapeutics, Inc. |
Use of catecholic butane derivatives in cancer therapy
|
|
TWI511956B
(zh)
|
2009-01-16 |
2015-12-11 |
Exelixis Inc |
製備ｎ-（４-｛〔６，７-雙（甲氧基）喹啉-４-基〕氧基｝苯基）-ｎ’-（４-氟苯基）環丙烷-１，１-二甲醯胺之方法
|
|
CN101787017A
(zh)
*
|
2009-01-23 |
2010-07-28 |
岑均达 |
光学纯喹唑啉类化合物
|
|
WO2010090764A1
(en)
|
2009-02-09 |
2010-08-12 |
Supergen, Inc. |
Pyrrolopyrimidinyl axl kinase inhibitors
|
|
WO2010099139A2
(en)
|
2009-02-25 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
|
JP2012519170A
(ja)
|
2009-02-26 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
|
|
TW201035088A
(en)
|
2009-02-27 |
2010-10-01 |
Supergen Inc |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
|
WO2010099363A1
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
JP2012519282A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
JP2012520893A
(ja)
|
2009-03-18 |
2012-09-10 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
Ｅｇｆｒ阻害薬及びｉｇｆ−１ｒ阻害剤の投与を含む組み合わせ癌治療
|
|
BRPI1006215A2
(pt)
|
2009-03-20 |
2019-09-24 |
Genentech Inc |
" anticorpos multiespecíficos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibição de uma atividade bíologica e uso do anticorpo "
|
|
EP2270002A1
(en)
|
2009-06-18 |
2011-01-05 |
Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg |
Quinazoline derivatives as histamine H4-receptor inhibitors for use in the treatment of inflammatory disorders
|
|
TWI691493B
(zh)
|
2009-06-29 |
2020-04-21 |
美商阿吉歐斯製藥公司 |
治療化合物及組成物
|
|
AU2010266725A1
(en)
|
2009-07-02 |
2012-02-23 |
Newgen Therapeutics, Inc. |
Phosphorus containing quinazoline compounds and methods of use
|
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
WO2011021597A1
(ja)
|
2009-08-19 |
2011-02-24 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
キノリン誘導体含有医薬組成物
|
|
ME02492B
(me)
|
2009-08-21 |
2017-02-20 |
Novartis Ag |
Lapatanib za lečenje kancera
|
|
JP2013503846A
(ja)
|
2009-09-01 |
2013-02-04 |
ファイザー・インク |
ベンズイミダゾール誘導体
|
|
TWI488851B
(zh)
|
2009-09-03 |
2015-06-21 |
必治妥美雅史谷比公司 |
作為鉀離子通道抑制劑之喹唑啉
|
|
KR101648787B1
(ko)
*
|
2009-09-28 |
2016-08-17 |
치루 파머수티컬 컴퍼니 리미티드 |
타이로신 키나제 억제제로서 유용한 4－（치환된 아닐리노）－퀴나졸린 유도체
|
|
MX2012005464A
(es)
|
2009-11-12 |
2012-06-08 |
Genentech Inc |
Un metodo para promover la densidad de espinas dendriticas.
|
|
CA2780875A1
(en)
|
2009-11-13 |
2011-05-19 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
|
WO2011079231A1
(en)
*
|
2009-12-23 |
2011-06-30 |
Gatekeeper Pharmaceutical, Inc. |
Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
|
|
CN102108079B
(zh)
*
|
2009-12-25 |
2014-10-01 |
齐鲁制药有限公司 |
作为酪氨酸激酶抑制剂的4-(取代苯胺基)喹唑啉衍生物
|
|
MX2012008049A
(es)
|
2010-01-12 |
2012-08-01 |
Hoffmann La Roche |
Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,.
|
|
EP3597651A1
(en)
|
2010-02-12 |
2020-01-22 |
Pfizer Inc |
Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one
|
|
CN102153544B
(zh)
*
|
2010-02-12 |
2015-04-29 |
上海阳帆医药科技有限公司 |
一类酪氨酸激酶抑制剂的制备及用途
|
|
US9556249B2
(en)
|
2010-02-18 |
2017-01-31 |
Genentech, Inc. |
Neuregulin antagonists and use thereof in treating cancer
|
|
AU2011223643A1
(en)
|
2010-03-03 |
2012-06-28 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
AU2011223655A1
(en)
|
2010-03-03 |
2012-06-28 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
|
BR112012023382A2
(pt)
|
2010-03-17 |
2018-05-15 |
F Hoffmann La Roche Ag T |
compostos, composições e métodos de uso de imidazopiridina.
|
|
AR088018A1
(es)
*
|
2010-03-23 |
2014-05-07 |
Scinopharm Taiwan Ltd |
Proceso e intermediarios para preparar lapatinib
|
|
WO2011120153A1
(en)
|
2010-04-01 |
2011-10-06 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of hiv
|
|
CA2793892A1
(en)
|
2010-04-16 |
2011-10-20 |
Elizabeth Punnoose |
Foxo3a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy
|
|
EP3135692B8
(en)
|
2010-06-16 |
2019-03-20 |
University of Pittsburgh - Of the Commonwealth System of Higher Education |
Antibodies to endoplasmin and their use
|
|
BR112012032462A2
(pt)
|
2010-06-25 |
2016-11-08 |
Eisai R&D Man Co Ltd |
agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
|
|
AU2011295919A1
(en)
|
2010-08-31 |
2013-03-07 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
|
KR20130051507A
(ko)
|
2010-09-15 |
2013-05-20 |
에프. 호프만-라 로슈 아게 |
아자벤조티아졸 화합물, 조성물 및 사용 방법
|
|
EP2630134B9
(en)
|
2010-10-20 |
2018-04-18 |
Pfizer Inc |
Pyridine-2- derivatives as smoothened receptor modulators
|
|
WO2012066061A1
(en)
|
2010-11-19 |
2012-05-24 |
F. Hoffmann-La Roche Ag |
Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors
|
|
CN102552271B
(zh)
*
|
2010-12-09 |
2014-08-06 |
中国科学院上海药物研究所 |
一类喹唑啉类化合物在制备抗黄病毒科病毒的药物中的用途
|
|
EP2468883A1
(en)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
|
US9134297B2
(en)
|
2011-01-11 |
2015-09-15 |
Icahn School Of Medicine At Mount Sinai |
Method and compositions for treating cancer and related methods
|
|
US20120214830A1
(en)
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
|
EP2492688A1
(en)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molecular biomarkers for predicting response to antitumor treatment in lung cancer
|
|
WO2012122058A2
(en)
|
2011-03-04 |
2012-09-13 |
Newgen Therapeutics, Inc. |
Alkyne substituted quinazoline compound and methods of use
|
|
EP2680844B1
(en)
|
2011-03-04 |
2016-10-19 |
GlaxoSmithKline Intellectual Property Development Limited |
Amino-quinolines as kinase inhibitors
|
|
CA2829219C
(en)
|
2011-03-09 |
2021-03-16 |
Richard G. Pestell |
Prostate cancer cell lines, gene signatures and uses thereof
|
|
WO2012125904A1
(en)
|
2011-03-17 |
2012-09-20 |
The Trustees Of The University Of Pennsylvania |
Mutation mimicking compounds that bind to the kinase domain of egfr
|
|
US9321759B2
(en)
|
2011-03-17 |
2016-04-26 |
The Trustees Of The University Of Pennsylvania |
Methods and use of bifunctional enzyme-building clamp-shaped molecules
|
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
|
US8962650B2
(en)
|
2011-04-18 |
2015-02-24 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
|
EP2699598B1
(en)
|
2011-04-19 |
2019-03-06 |
Pfizer Inc |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
|
JP2014519813A
(ja)
|
2011-04-25 |
2014-08-21 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
|
|
WO2012155339A1
(zh)
|
2011-05-17 |
2012-11-22 |
江苏康缘药业股份有限公司 |
4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
|
|
ES2705950T3
(es)
|
2011-06-03 |
2019-03-27 |
Eisai R&D Man Co Ltd |
Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
|
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
|
US9416132B2
(en)
|
2011-07-21 |
2016-08-16 |
Tolero Pharmaceuticals, Inc. |
Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
|
|
KR20140047160A
(ko)
|
2011-08-12 |
2014-04-21 |
에프. 호프만-라 로슈 아게 |
인다졸 화합물, 조성물 및 사용 방법
|
|
RU2014109093A
(ru)
|
2011-08-17 |
2015-09-27 |
Дженентек, Инк. |
Антитела против нейрегулина и их применение
|
|
TWI547494B
(zh)
|
2011-08-18 |
2016-09-01 |
葛蘭素史克智慧財產發展有限公司 |
作為激酶抑制劑之胺基喹唑啉類
|
|
CA2845179A1
(en)
|
2011-08-31 |
2013-03-07 |
Genentech, Inc. |
Diagnostic markers
|
|
EP2758397A1
(en)
|
2011-09-20 |
2014-07-30 |
F.Hoffmann-La Roche Ag |
Imidazopyridine compounds, compositions and methods of use
|
|
BR112014006840A2
(pt)
|
2011-09-22 |
2017-04-04 |
Pfizer |
derivados de pirrolopirimidina e purina
|
|
EP2761025A1
(en)
|
2011-09-30 |
2014-08-06 |
Genentech, Inc. |
Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
|
|
US9783613B2
(en)
|
2011-10-04 |
2017-10-10 |
Igem Therapeutics Limited |
IgE anti-HMW-MAA antibody
|
|
WO2013060881A1
(en)
|
2011-10-27 |
2013-05-02 |
Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg |
Pyridopyrimidines and their therapeutic use
|
|
RU2014114015A
(ru)
|
2011-11-08 |
2015-12-20 |
Пфайзер Инк. |
Способы лечения воспалительных расстройств с использованием антител против m-csf
|
|
MX2014006529A
(es)
|
2011-11-30 |
2014-11-25 |
Genentech Inc |
Mutaciones de erbb3 en cancer.
|
|
US9546179B2
(en)
|
2011-12-20 |
2017-01-17 |
Wei Qian |
Heterocycle amido alkyloxy substituted quinazoline derivative and use thereof
|
|
CN104204226A
(zh)
|
2012-01-31 |
2014-12-10 |
史密斯克莱.比奇曼（科克）有限公司 |
治疗癌症的方法
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
AU2013240261A1
(en)
|
2012-03-27 |
2014-09-18 |
Genentech, Inc. |
Diagnosis and treatments relating to HER3 inhibitors
|
|
EP3964513A1
(en)
|
2012-04-03 |
2022-03-09 |
Novartis AG |
Combination products with tyrosine kinase inhibitors and their use
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
CA2873743C
(en)
|
2012-05-14 |
2022-12-06 |
Prostagene, Llc |
Using modulators of ccr5 for treating cancer
|
|
WO2013190089A1
(en)
|
2012-06-21 |
2013-12-27 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting outcome in lung cancer
|
|
TWI592417B
(zh)
|
2012-09-13 |
2017-07-21 |
葛蘭素史克智慧財產發展有限公司 |
胺基喹唑啉激酶抑制劑之前藥
|
|
AR092530A1
(es)
|
2012-09-13 |
2015-04-22 |
Glaxosmithkline Llc |
Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
|
|
US9394257B2
(en)
|
2012-10-16 |
2016-07-19 |
Tolero Pharmaceuticals, Inc. |
PKM2 modulators and methods for their use
|
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
|
CN104755463A
(zh)
|
2012-12-21 |
2015-07-01 |
卫材R&D管理有限公司 |
非晶态形式的喹啉衍生物及其生产方法
|
|
ES2654100T3
(es)
|
2013-02-21 |
2018-02-12 |
Glaxosmithkline Intellectual Property Development Limited |
Quinazolinas como inhibidores de quinasa
|
|
HK1211235A1
(en)
|
2013-02-22 |
2016-05-20 |
霍夫曼-拉罗奇有限公司 |
Methods of treating cancer and preventing drug resistance
|
|
EP2961412A4
(en)
|
2013-02-26 |
2016-11-09 |
Triact Therapeutics Inc |
CANCER THERAPY
|
|
US9468681B2
(en)
|
2013-03-01 |
2016-10-18 |
California Institute Of Technology |
Targeted nanoparticles
|
|
RU2015137610A
(ru)
|
2013-03-06 |
2017-04-10 |
Дженентек, Инк. |
Способы лечения и профилактики лекарственной резистентности злокачественных опухолей
|
|
CN105980386B
(zh)
|
2013-03-13 |
2021-08-13 |
基因泰克公司 |
吡唑并化合物及其用途
|
|
RU2019119893A
(ru)
|
2013-03-14 |
2019-08-09 |
Толеро Фармасьютикалз, Инк. |
Ингибиторы jak2 и alk2 и способы их использования
|
|
AU2014239903A1
(en)
|
2013-03-14 |
2015-09-17 |
Genentech, Inc. |
Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use
|
|
BR112015022604A2
(pt)
|
2013-03-14 |
2017-10-24 |
Genentech Inc |
usos de um modulador de modificador de cromatina e um antagonista de egfr
|
|
KR20150130451A
(ko)
|
2013-03-15 |
2015-11-23 |
제넨테크, 인크. |
암 치료 방법 및 항암제 내성 예방을 위한 방법
|
|
WO2014147246A1
(en)
|
2013-03-21 |
2014-09-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
|
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
|
JP6411379B2
(ja)
|
2013-05-14 |
2018-10-24 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
CN105611933B
(zh)
|
2013-09-05 |
2019-01-25 |
基因泰克公司 |
抗增生性化合物
|
|
US9381246B2
(en)
|
2013-09-09 |
2016-07-05 |
Triact Therapeutics, Inc. |
Cancer therapy
|
|
AR097894A1
(es)
|
2013-10-03 |
2016-04-20 |
Hoffmann La Roche |
Inhibidores terapéuticos de cdk8 o uso de los mismos
|
|
ES2775579T3
(es)
|
2013-10-04 |
2020-07-27 |
Aptose Biosciences Inc |
Composiciones para el tratamiento del cáncer
|
|
KR20160070136A
(ko)
|
2013-10-18 |
2016-06-17 |
제넨테크, 인크. |
항-rspo2 및/또는 항-rspo3 항체 및 그의 용도
|
|
CN103554091B
(zh)
*
|
2013-11-05 |
2016-05-18 |
沈阳工业大学 |
喹唑啉衍生物及其制备方法和用途
|
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
|
US9815797B2
(en)
*
|
2013-12-09 |
2017-11-14 |
Ucb Biopharma Sprl |
Fused bicyclic heteroaromatic derivatives as modulators of TNF activity
|
|
AU2014364606A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
|
EP3647324A1
(en)
|
2013-12-17 |
2020-05-06 |
F. Hoffmann-La Roche AG |
Methods of treating cancers using pd-1 axis binding antagonists and taxanes
|
|
JP2017516458A
(ja)
|
2014-03-24 |
2017-06-22 |
ジェネンテック， インコーポレイテッド |
ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関
|
|
EP3126386A1
(en)
|
2014-03-31 |
2017-02-08 |
F. Hoffmann-La Roche AG |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
|
CR20160500A
(es)
|
2014-03-31 |
2016-12-14 |
Genentech Inc |
Anticuerpos anti-ox40 y métodos de uso
|
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
|
WO2015156674A2
(en)
|
2014-04-10 |
2015-10-15 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
|
ES2759434T3
(es)
|
2014-04-30 |
2020-05-11 |
Pfizer |
Derivados de diheterociclo unidos a cicloalquilo
|
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
|
JP6811706B2
(ja)
|
2014-07-31 |
2021-01-13 |
ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー |
Ｅｐｈａ４に対するヒトモノクローナル抗体及びそれらの使用
|
|
DK3524595T3
(da)
|
2014-08-28 |
2022-09-19 |
Eisai R&D Man Co Ltd |
Quinolinderivat af høj renhed og fremgangsmåde til fremstilling deraf
|
|
WO2016036873A1
(en)
|
2014-09-05 |
2016-03-10 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
CN107073125A
(zh)
|
2014-09-19 |
2017-08-18 |
基因泰克公司 |
Cbp/ep300和bet抑制剂用于治疗癌症的用途
|
|
WO2016057924A1
(en)
|
2014-10-10 |
2016-04-14 |
Genentech, Inc. |
Pyrrolidine amide compounds as histone demethylase inhibitors
|
|
US20170252335A1
(en)
|
2014-10-17 |
2017-09-07 |
Novartis Ag |
Combination of Ceritinib with an EGFR Inhibitor
|
|
SG11201703521UA
(en)
|
2014-11-03 |
2017-05-30 |
Genentech Inc |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
|
RU2017119009A
(ru)
|
2014-11-03 |
2018-12-05 |
Дженентек, Инк. |
Анализы для обнаружения субпопуляций иммунных т-клеток и способы их применения
|
|
EP3215536A1
(en)
|
2014-11-06 |
2017-09-13 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
|
MA40943A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
|
MA40940A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
|
CN107108613B
(zh)
|
2014-11-10 |
2020-02-25 |
基因泰克公司 |
布罗莫结构域抑制剂及其用途
|
|
JP2017537090A
(ja)
|
2014-11-17 |
2017-12-14 |
ジェネンテック， インコーポレイテッド |
Ｏｘ４０結合アゴニスト及びｐｄ−１軸結合アンタゴニストを含む併用療法
|
|
EP3632915A1
(en)
|
2014-11-27 |
2020-04-08 |
Genentech, Inc. |
4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
|
|
US10206924B2
(en)
|
2014-12-15 |
2019-02-19 |
The Regents Of The University Of Michigan |
Small molecule inhibitors of EGFR and PI3K
|
|
JP6621477B2
(ja)
|
2014-12-18 |
2019-12-18 |
ファイザー・インク |
ピリミジンおよびトリアジン誘導体ならびにａｘｌ阻害薬としてのそれらの使用
|
|
MX2017006864A
(es)
|
2014-12-23 |
2017-08-28 |
Genentech Inc |
Composiciones y métodos para tratar y diagnosticar cánceres resistentes a la quimioterapia.
|
|
JP6900314B2
(ja)
|
2014-12-24 |
2021-07-07 |
ジェネンテック， インコーポレイテッド |
膀胱癌の治療、診断、及び予後判定方法
|
|
EP3240908A2
(en)
|
2014-12-30 |
2017-11-08 |
F. Hoffmann-La Roche AG |
Methods and compositions for prognosis and treatment of cancers
|
|
JP6855379B2
(ja)
|
2015-01-09 |
2021-04-07 |
ジェネンテック， インコーポレイテッド |
癌の処置のためのヒストンデメチラーゼｋｄｍ２ｂのインヒビターとしての（ピペリジン−３−イル）（ナフタレン−２−イル）メタノン誘導体および関連化合物
|
|
WO2016112298A1
(en)
|
2015-01-09 |
2016-07-14 |
Genentech, Inc. |
Pyridazinone derivatives and their use in the treatment of cancer
|
|
EP3242875B1
(en)
|
2015-01-09 |
2022-02-23 |
Genentech, Inc. |
4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
|
|
JP6709792B2
(ja)
|
2015-01-29 |
2020-06-17 |
ジェネンテック， インコーポレイテッド |
治療用化合物およびその使用
|
|
CN107438593B
(zh)
|
2015-01-30 |
2020-10-30 |
基因泰克公司 |
治疗化合物及其用途
|
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
|
DK3263106T3
(da)
|
2015-02-25 |
2024-01-08 |
Eisai R&D Man Co Ltd |
Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
|
|
WO2016140717A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
|
WO2016164480A1
(en)
|
2015-04-07 |
2016-10-13 |
Genentech, Inc. |
Antigen binding complex having agonistic activity and methods of use
|
|
US9901574B2
(en)
|
2015-04-20 |
2018-02-27 |
Tolero Pharmaceuticals, Inc. |
Predicting response to alvocidib by mitochondrial profiling
|
|
CN107709344B
(zh)
|
2015-05-01 |
2022-07-15 |
共晶制药股份有限公司 |
用于治疗黄病毒科病毒和癌症的核苷类似物
|
|
DK3294770T4
(da)
|
2015-05-12 |
2024-05-21 |
Hoffmann La Roche |
Terapeutiske og diagnostiske fremgangsmåder til cancer
|
|
EP3527574B1
(en)
|
2015-05-18 |
2022-04-06 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs having increased bioavailability
|
|
IL255372B
(en)
|
2015-05-29 |
2022-07-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
|
JP2018518483A
(ja)
|
2015-06-08 |
2018-07-12 |
ジェネンテック， インコーポレイテッド |
抗ｏｘ４０抗体及びｐｄ−１軸結合アンタゴニストを使用して癌を治療する方法
|
|
EP3303399A1
(en)
|
2015-06-08 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Methods of treating cancer using anti-ox40 antibodies
|
|
US11369623B2
(en)
|
2015-06-16 |
2022-06-28 |
Prism Pharma Co., Ltd. |
Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
|
|
CA2986263A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
|
WO2017003668A1
(en)
|
2015-07-01 |
2017-01-05 |
California Institute Of Technology |
Cationic mucic acid polymer-based delivery systems
|
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
|
US10568887B2
(en)
|
2015-08-03 |
2020-02-25 |
Tolero Pharmaceuticals, Inc. |
Combination therapies for treatment of cancer
|
|
MX381976B
(es)
|
2015-08-20 |
2025-03-13 |
Eisai R&D Man Co Ltd |
Agente terapéutico contra tumores.
|
|
WO2017033019A1
(en)
|
2015-08-26 |
2017-03-02 |
Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii (Cnio) |
Condensed tricyclic compounds as protein kinase inhibitors
|
|
LT3353210T
(lt)
|
2015-09-25 |
2025-01-27 |
F. Hoffmann-La Roche Ag |
Antikūnai prieš tigit ir jų naudojimo būdai
|
|
MX2018004109A
(es)
|
2015-10-05 |
2018-09-27 |
Univ Columbia |
Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
|
|
SG11201804360XA
(en)
|
2015-12-03 |
2018-06-28 |
Agios Pharmaceuticals Inc |
Mat2a inhibitors for treating mtap null cancer
|
|
PL3978500T3
(pl)
|
2015-12-16 |
2024-03-11 |
Genentech, Inc. |
Sposób wytwarzania tricyklicznych związków inhibitorów pi3k
|
|
US10596257B2
(en)
|
2016-01-08 |
2020-03-24 |
Hoffmann-La Roche Inc. |
Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
|
|
MX2018010361A
(es)
|
2016-02-29 |
2019-07-08 |
Genentech Inc |
Métodos terapéuticos y de diagnóstico para el cáncer.
|
|
EP3424928A4
(en)
|
2016-03-01 |
2019-10-09 |
Shanghai Pharmaceuticals Holding Co., Ltd. |
NITROGENIC HETEROCYCLIC COMPOUND, MANUFACTURING METHOD, INTERMEDIATE PRODUCT, COMPOSITION AND USE
|
|
MX2018010851A
(es)
|
2016-03-08 |
2019-02-07 |
Janssen Biotech Inc |
Anticuerpos de gitr, métodos, y usos.
|
|
WO2017180864A1
(en)
|
2016-04-14 |
2017-10-19 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
|
PL3443350T3
(pl)
|
2016-04-15 |
2021-05-31 |
F. Hoffmann-La Roche Ag |
Sposoby monitorowania i leczenia nowotworu
|
|
AU2017249229A1
(en)
|
2016-04-15 |
2018-10-04 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
AU2017248766A1
(en)
|
2016-04-15 |
2018-11-01 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
|
JP7160688B2
(ja)
|
2016-05-24 |
2022-10-25 |
ジェネンテック， インコーポレイテッド |
Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用
|
|
MA45146A
(fr)
|
2016-05-24 |
2021-03-24 |
Constellation Pharmaceuticals Inc |
Dérivés de pyrazolopyridine pour le traitement du cancer
|
|
WO2017214373A1
(en)
|
2016-06-08 |
2017-12-14 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
EP3484499A4
(en)
|
2016-07-14 |
2020-05-13 |
Scholar Rock, Inc. |
TGFB ANTIBODIES, METHODS AND USE
|
|
CN109963871A
(zh)
|
2016-08-05 |
2019-07-02 |
豪夫迈·罗氏有限公司 |
具有激动活性的多价及多表位抗体以及使用方法
|
|
JP7250674B2
(ja)
|
2016-08-08 |
2023-04-03 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療及び診断方法
|
|
CA3038712A1
(en)
|
2016-10-06 |
2018-04-12 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
EP3532091A2
(en)
|
2016-10-29 |
2019-09-04 |
H. Hoffnabb-La Roche Ag |
Anti-mic antibidies and methods of use
|
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
CN110234659A
(zh)
|
2016-12-19 |
2019-09-13 |
特雷罗药物股份有限公司 |
用于敏感性分析的分析肽和方法
|
|
SG11201906223TA
(en)
|
2016-12-22 |
2019-08-27 |
Amgen Inc |
Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
|
|
WO2018147275A1
(ja)
|
2017-02-08 |
2018-08-16 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療用医薬組成物
|
|
KR20190134631A
(ko)
|
2017-03-01 |
2019-12-04 |
제넨테크, 인크. |
암의 진단 및 치료 방법
|
|
KR20190136076A
(ko)
|
2017-04-13 |
2019-12-09 |
에프. 호프만-라 로슈 아게 |
암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
|
|
CA3061888A1
(en)
|
2017-05-16 |
2018-11-22 |
Eisai R&D Management Co., Ltd. |
Treatment of hepatocellular carcinoma
|
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
|
KR20200093518A
(ko)
|
2017-07-21 |
2020-08-05 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
EP3665197A2
(en)
|
2017-08-11 |
2020-06-17 |
H. Hoffnabb-La Roche Ag |
Anti-cd8 antibodies and uses thereof
|
|
JP7333313B2
(ja)
|
2017-09-01 |
2023-08-24 |
シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド |
窒素含有複素環化合物、製造方法、中間体、組成物および使用
|
|
WO2019051296A1
(en)
|
2017-09-08 |
2019-03-14 |
Genentech, Inc. |
DIAGNOSTIC AND THERAPEUTIC METHODS OF CANCER
|
|
EP4403175A3
(en)
|
2017-09-08 |
2024-10-02 |
Amgen Inc. |
Inhibitors of kras g12c and methods of using the same
|
|
WO2019055579A1
(en)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
|
|
US20200237766A1
(en)
|
2017-10-13 |
2020-07-30 |
Tolero Pharmaceuticals, Inc. |
Pkm2 activators in combination with reactive oxygen species for treatment of cancer
|
|
WO2019084395A1
(en)
|
2017-10-27 |
2019-05-02 |
University Of Virginia Patent Foundation |
COMPOUNDS AND METHODS FOR REGULATING, LIMITING OR INHIBITING AVIL EXPRESSION
|
|
WO2019090263A1
(en)
|
2017-11-06 |
2019-05-09 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
CA3085593A1
(en)
|
2017-12-18 |
2019-06-27 |
Sterngreene, Inc. |
Pyrimidine compounds useful as tyrosine kinase inhibitors
|
|
JP7236164B2
(ja)
|
2018-01-15 |
2023-03-09 |
エピアクシス セラピューティクス プロプライエタリー リミテッド |
治療法に対する応答を予測する薬剤及び方法
|
|
MX2020008882A
(es)
|
2018-02-26 |
2021-01-08 |
Genentech Inc |
Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
|
|
MA52501A
(fr)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
|
JP7361722B2
(ja)
|
2018-05-04 |
2023-10-16 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤及び同一物の使用方法
|
|
CA3099045A1
(en)
|
2018-05-10 |
2019-11-14 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
|
CA3100200A1
(en)
|
2018-05-21 |
2019-11-28 |
Nanostring Technologies, Inc. |
Molecular gene signatures and methods of using same
|
|
MX2020012731A
(es)
|
2018-06-01 |
2021-02-22 |
Amgen Inc |
Inhibidores de kras g12c y metodos para su uso.
|
|
MX2020012204A
(es)
|
2018-06-11 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c para tratar el cáncer.
|
|
MX2020012261A
(es)
|
2018-06-12 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
|
|
WO2019241327A1
(en)
|
2018-06-13 |
2019-12-19 |
California Institute Of Technology |
Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
|
|
SG11202012446UA
(en)
|
2018-06-23 |
2021-01-28 |
Genentech Inc |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
|
US20200171146A1
(en)
|
2018-07-18 |
2020-06-04 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
|
KR20210038906A
(ko)
|
2018-07-26 |
2021-04-08 |
스미토모 다이니폰 파마 온콜로지, 인크. |
비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
|
|
EP3847154A1
(en)
|
2018-09-03 |
2021-07-14 |
F. Hoffmann-La Roche AG |
Carboxamide and sulfonamide derivatives useful as tead modulators
|
|
AU2019342099A1
(en)
|
2018-09-19 |
2021-04-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
|
CA3111809A1
(en)
|
2018-09-21 |
2020-03-26 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
|
EP3860608A1
(en)
|
2018-10-04 |
2021-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Egfr inhibitors for treating keratodermas
|
|
US12404540B2
(en)
|
2018-10-17 |
2025-09-02 |
The University Of Queensland |
Epigenetic biomarker and uses therefor
|
|
EP3867646A1
(en)
|
2018-10-18 |
2021-08-25 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
|
|
WO2020106640A1
(en)
|
2018-11-19 |
2020-05-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
|
|
JP2022511029A
(ja)
|
2018-12-04 |
2022-01-28 |
スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド |
がんの処置のための薬剤としての使用のためのｃｄｋ９インヒビターおよびその多形
|
|
EP3898626A1
(en)
|
2018-12-19 |
2021-10-27 |
Array Biopharma, Inc. |
Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
|
|
EP3898615A1
(en)
|
2018-12-19 |
2021-10-27 |
Array Biopharma, Inc. |
7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
|
|
WO2020132653A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
|
MX2021007104A
(es)
|
2018-12-20 |
2021-08-11 |
Amgen Inc |
Inhibidores de kif18a.
|
|
US12441705B2
(en)
|
2018-12-20 |
2025-10-14 |
Amgen Inc. |
KIF18A inhibitors
|
|
TWI844602B
(zh)
|
2018-12-20 |
2024-06-11 |
美商安進公司 |
Kif18a抑制劑
|
|
EP3921443A1
(en)
|
2019-02-08 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
|
WO2020167990A1
(en)
|
2019-02-12 |
2020-08-20 |
Tolero Pharmaceuticals, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
JP7520389B2
(ja)
|
2019-02-27 |
2024-07-23 |
エピアクシス セラピューティクス プロプライエタリー リミテッド |
Ｔ細胞機能を評価して治療法に対する応答を予測するための方法および薬剤
|
|
JP2022521773A
(ja)
|
2019-02-27 |
2022-04-12 |
ジェネンテック， インコーポレイテッド |
抗ｔｉｇｉｔ抗体と抗ｃｄ２０抗体又は抗ｃｄ３８抗体とによる処置のための投薬
|
|
JP2022522777A
(ja)
|
2019-03-01 |
2022-04-20 |
レボリューション メディシンズ インコーポレイテッド |
二環式ヘテロアリール化合物及びその使用
|
|
AU2020232616A1
(en)
|
2019-03-01 |
2021-09-09 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
|
WO2020191326A1
(en)
|
2019-03-20 |
2020-09-24 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (aml) with venetoclax failure
|
|
WO2020198077A1
(en)
|
2019-03-22 |
2020-10-01 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
|
TWI879768B
(zh)
|
2019-05-03 |
2025-04-11 |
美商建南德克公司 |
用抗pd-l1抗體治療癌症之方法
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
CN118834208A
(zh)
|
2019-05-21 |
2024-10-25 |
美国安进公司 |
固态形式
|
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
|
ES3051917T3
(en)
|
2019-08-02 |
2025-12-30 |
Amgen Inc |
Kif18a inhibitors
|
|
MX2022001296A
(es)
|
2019-08-02 |
2022-02-22 |
Amgen Inc |
Inhibidores de kif18a.
|
|
MX2022001302A
(es)
|
2019-08-02 |
2022-03-02 |
Amgen Inc |
Inhibidores de kif18a.
|
|
CA3147451A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
|
JP7743396B2
(ja)
|
2019-09-04 |
2025-09-24 |
ジェネンテック， インコーポレイテッド |
Ｃｄ８結合性作用剤およびその使用
|
|
JP2022548978A
(ja)
|
2019-09-27 |
2022-11-22 |
ジェネンテック， インコーポレイテッド |
薬抗ｔｉｇｉｔ及び抗ｐｄ－ｌ１アンタゴニスト抗体を用いた処置のための投薬
|
|
EP4048671A1
(en)
|
2019-10-24 |
2022-08-31 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
|
|
WO2021083949A1
(en)
|
2019-10-29 |
2021-05-06 |
F. Hoffmann-La Roche Ag |
Bifunctional compounds for the treatment of cancer
|
|
JP2022553858A
(ja)
|
2019-11-04 |
2022-12-26 |
レボリューション メディシンズ インコーポレイテッド |
Ｒａｓ阻害剤
|
|
CN114867735A
(zh)
|
2019-11-04 |
2022-08-05 |
锐新医药公司 |
Ras抑制剂
|
|
MX2022005357A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
|
CN115066613A
(zh)
|
2019-11-06 |
2022-09-16 |
基因泰克公司 |
用于治疗血液癌症的诊断和治疗方法
|
|
KR20220100903A
(ko)
|
2019-11-08 |
2022-07-18 |
레볼루션 메디슨즈, 인크. |
이환식 헤테로아릴 화합물 및 이의 용도
|
|
CN112778217B
(zh)
*
|
2019-11-08 |
2024-01-26 |
沈阳化工研究院有限公司 |
一种喹唑啉类化合物及其应用
|
|
TW202130618A
(zh)
|
2019-11-13 |
2021-08-16 |
美商建南德克公司 |
治療性化合物及使用方法
|
|
CN114728960B
(zh)
|
2019-11-14 |
2025-05-27 |
美国安进公司 |
Kras g12c抑制剂化合物的改善的合成
|
|
EP4058432A1
(en)
|
2019-11-14 |
2022-09-21 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
AU2020403145B2
(en)
|
2019-12-13 |
2025-06-26 |
Genentech, Inc. |
Anti-Ly6G6D antibodies and methods of use
|
|
WO2021127404A1
(en)
|
2019-12-20 |
2021-06-24 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
TW202140011A
(zh)
|
2020-01-07 |
2021-11-01 |
美商銳新醫藥公司 |
Shp2抑制劑給藥和治療癌症的方法
|
|
EP4096646A1
(en)
|
2020-01-27 |
2022-12-07 |
Genentech, Inc. |
Methods for treatment of cancer with an anti-tigit antagonist antibody
|
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
|
WO2021222167A1
(en)
|
2020-04-28 |
2021-11-04 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
|
KR20230025691A
(ko)
|
2020-06-16 |
2023-02-22 |
제넨테크, 인크. |
삼중 음성 유방암을 치료하기 위한 방법과 조성물
|
|
BR112022025550A2
(pt)
|
2020-06-18 |
2023-03-07 |
Revolution Medicines Inc |
Métodos para retardar, prevenir e tratar resistência adquirida aos inibidores de ras
|
|
MX2022015881A
(es)
|
2020-06-18 |
2023-01-24 |
Genentech Inc |
Tratamiento con anticuerpos anti-tigit y antagonistas de union al eje de pd-1.
|
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
CN116568824A
(zh)
|
2020-08-03 |
2023-08-08 |
基因泰克公司 |
淋巴瘤的诊断和治疗方法
|
|
WO2022036146A1
(en)
|
2020-08-12 |
2022-02-17 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
KR20230081726A
(ko)
|
2020-09-03 |
2023-06-07 |
레볼루션 메디슨즈, 인크. |
Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도
|
|
TW202227460A
(zh)
|
2020-09-15 |
2022-07-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
IL301524A
(en)
|
2020-09-23 |
2023-05-01 |
Erasca Inc |
Tricyclic pyridones and pyrimidones
|
|
CN116406291A
(zh)
|
2020-10-05 |
2023-07-07 |
基因泰克公司 |
用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
|
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
EP4267554A1
(en)
|
2020-12-22 |
2023-11-01 |
Mekanistic Therapeutics LLC |
Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors
|
|
TW202241885A
(zh)
|
2020-12-22 |
2022-11-01 |
大陸商上海齊魯銳格醫藥研發有限公司 |
Ｓｏｓ１抑制劑及其用途
|
|
MX2023009379A
(es)
|
2021-02-12 |
2023-10-10 |
Hoffmann La Roche |
Derivados de tetrahidroazepina biciclicos para el tratamiento del cancer.
|
|
US12252497B2
(en)
|
2021-05-05 |
2025-03-18 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
JP2024516450A
(ja)
|
2021-05-05 |
2024-04-15 |
レボリューション メディシンズ インコーポレイテッド |
共有結合性ｒａｓ阻害剤及びその使用
|
|
MX2023013085A
(es)
|
2021-05-05 |
2023-11-16 |
Revolution Medicines Inc |
Inhibidores de ras.
|
|
AU2022280025A1
(en)
|
2021-05-25 |
2023-12-07 |
Erasca, Inc. |
Sulfur-containing heteroaromatic tricyclic kras inhibitors
|
|
US20240293558A1
(en)
|
2021-06-16 |
2024-09-05 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
WO2023018699A1
(en)
|
2021-08-10 |
2023-02-16 |
Erasca, Inc. |
Selective kras inhibitors
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
EP4436957A1
(en)
|
2021-11-24 |
2024-10-02 |
Genentech, Inc. |
Therapeutic indazole compounds and methods of use in the treatment of cancer
|
|
EP4436969A2
(en)
|
2021-11-24 |
2024-10-02 |
Genentech, Inc. |
Bicyclic therapeutic compounds and methods of use in the treatment of cancer
|
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
MX2024010828A
(es)
|
2022-03-07 |
2024-09-17 |
Amgen Inc |
Procedimiento para preparar 4-metil-2-propan-2-il-piridin-3-carbon itrilo.
|
|
JP2025510572A
(ja)
|
2022-03-08 |
2025-04-15 |
レボリューション メディシンズ インコーポレイテッド |
免疫不応性肺癌を治療するための方法
|
|
CA3246312A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES
|
|
EP4522653A1
(en)
|
2022-05-11 |
2025-03-19 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
|
AU2023285116A1
(en)
|
2022-06-10 |
2024-12-19 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
CN119585308A
(zh)
|
2022-07-13 |
2025-03-07 |
基因泰克公司 |
针对用抗fcrh5/抗cd3双特异性抗体进行的治疗的给药
|
|
EP4558524A1
(en)
|
2022-07-19 |
2025-05-28 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
TW202417001A
(zh)
|
2022-08-11 |
2024-05-01 |
瑞士商赫孚孟拉羅股份公司 |
雙環四氫吖呯衍生物
|
|
TW202417439A
(zh)
|
2022-08-11 |
2024-05-01 |
瑞士商赫孚孟拉羅股份公司 |
雙環四氫噻吖呯衍生物
|
|
KR20250048020A
(ko)
|
2022-08-11 |
2025-04-07 |
에프. 호프만-라 로슈 아게 |
바이시클릭 테트라히드로티아제핀 유도체
|
|
PE20251399A1
(es)
|
2022-08-11 |
2025-05-22 |
Hoffmann La Roche |
Derivados de tetrahidrotiazepina biciclicos
|
|
CR20250141A
(es)
|
2022-10-14 |
2025-05-26 |
Black Diamond Therapeutics Inc |
Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina
|
|
WO2024085242A2
(en)
|
2022-10-21 |
2024-04-25 |
Kawasaki Institute Of Industrial Promotion |
Non-fouling or super stealth vesicle
|
|
TW202426505A
(zh)
|
2022-10-25 |
2024-07-01 |
美商建南德克公司 |
癌症之治療及診斷方法
|
|
TW202434206A
(zh)
|
2023-02-17 |
2024-09-01 |
美商伊瑞斯卡公司 |
Ｋｒａｓ抑制劑
|
|
WO2024206858A1
(en)
|
2023-03-30 |
2024-10-03 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
WO2024211712A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
WO2024211663A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
TW202448897A
(zh)
|
2023-04-14 |
2024-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
|
|
WO2024216016A1
(en)
|
2023-04-14 |
2024-10-17 |
Revolution Medicines, Inc. |
Crystalline forms of a ras inhibitor
|
|
WO2024229406A1
(en)
|
2023-05-04 |
2024-11-07 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
WO2024233341A1
(en)
|
2023-05-05 |
2024-11-14 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2024254455A1
(en)
|
2023-06-08 |
2024-12-12 |
Genentech, Inc. |
Macrophage signatures for diagnostic and therapeutic methods for lymphoma
|
|
WO2025024257A1
(en)
|
2023-07-21 |
2025-01-30 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
TW202515614A
(zh)
|
2023-08-25 |
2025-04-16 |
美商建南德克公司 |
治療非小細胞肺癌之方法及組成物
|
|
WO2025080946A2
(en)
|
2023-10-12 |
2025-04-17 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025137507A1
(en)
|
2023-12-22 |
2025-06-26 |
Regor Pharmaceuticals, Inc. |
Sos1 inhibitors and uses thereof
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|